To include your compound in the COVID-19 Resource Center, submit it here.

Axsome starts Ph III of AXS-05 to treat agitation in AD patients

Axsome Therapeutics Inc. (NASDAQ:AXSM) began the Phase II/III ADVANCE-1 trial of AXS-05 to treat agitation in

Read the full 160 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE